Cell surface phenotype profiles distinguish stable and progressive chronic lymphocytic leukemia

Leukemia and Lymphoma

Volumn 55, Issue 9, 2014, Pages 2085-2092

  Huang, Pauline Y ^a   Best, Oliver G ^b   Almazi, Juhura G ^a   Belov, Larissa ^a   Davis, Zadie A ^c   Majid, Aneela ^d   Dyer, Martin J ^d   Pascovici, Dana ^e   Mulligan, Stephen P ^a,b   Christopherson, Richard I ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ROYAL NORTH SHORE HOSPITAL   (Australia)

^c ROYAL BOURNEMOUTH HOSPITAL   (United Kingdom)

^d UNIVERSITY OF LEICESTER   (United Kingdom)

^e MACQUARIE UNIVERSITY   (Australia)

Author keywords

antibody microarray; CD antigens; Chronic lymphocytic leukemia; immunophenotype; prognosis

Indexed keywords

ANTIGEN; CD11B ANTIGEN; CD148 ANTIGEN; CD18 ANTIGEN; CD180 ANTIGEN; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD24 ANTIGEN; CD270 ANTIGEN; CD38 ANTIGEN; CD40 ANTIGEN; CD45 ANTIGEN; CD45RA ANTIGEN; CD52 ANTIGEN; CD69 ANTIGEN; CD81 ANTIGEN; CD84 ANTIGEN; CD98 ANTIGEN; CHEMOKINE RECEPTOR CCR6; COMPLEMENT COMPONENT C3D RECEPTOR; GLYCOPROTEIN P 15095; INTERCELLULAR ADHESION MOLECULE 2; INTERLEUKIN 2 RECEPTOR ALPHA; LEUKOSIALIN; LYMPHOCYTE FUNCTION ASSOCIATED ANTIGEN 1; UNCLASSIFIED DRUG; MEMBRANE ANTIGEN;

ACCURACY; ARTICLE; CANCER GROWTH; CELL SURFACE; CHRONIC LYMPHATIC LEUKEMIA; HUMAN; HUMAN CELL; MICROARRAY ANALYSIS; PHENOTYPE; PRIORITY JOURNAL; B LYMPHOCYTE; CLUSTER ANALYSIS; DISEASE COURSE; GENETICS; IMMUNOPHENOTYPING; METABOLISM; PATHOLOGY; PROCEDURES; PROGNOSIS; REPRODUCIBILITY;

ANTIGENS, SURFACE; B-LYMPHOCYTES; CLUSTER ANALYSIS; DISEASE PROGRESSION; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; PHENOTYPE; PROGNOSIS; REPRODUCIBILITY OF RESULTS;

EID: 84906058836     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2013.867486     Document Type: Article

References (70)

1. Shanafelt TD, Geyer SM, Kay NE. Prognosis at diagnosis: integrating molecular biologic insights into clinical practice for patients with CLL. Blood 2004; 103: 1202-1210.
2. Kay NE, Jelinek DF. B-CLL: is the enigma of disease heterogeneity about to be revealed? Blood 2002; 100: 1110-1111.
3. Rai KR, Sawitsky A, Cronkite EP, et al. Clinical staging of chronic lymphocytic leukemia. Blood 1975; 46: 219-234.
4. Binet JL, Lepoprier M, Dighiero G, et al. A clinical staging system for chronic lymphocytic leukemia: prognostic significance. Cancer 1977; 40: 855-864.
5. D amle R N, W asil T, F ais F, et al. Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukemia. Blood 1999; 94: 1840-1847.
6. Hamblin TJ, Davis Z, Gardiner A, et al. Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukemia. Blood 1999; 94: 1848-1854.
7. Orchard JA, Ibbotson RE, Davis Z, et al. ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet 2004; 363: 105-111.
8. D ohner H, S tilgenbauer S, B enner A, et al. Genomic aberrations and survival in chronic lymphocytic leukemia. N Engl J Med 2000; 343: 1910-1916.
9. L etestu R, R awstron A, G hia P, et al. Evaluation of ZAP-70 expression by flow cytometrYin chronic lymphocytic leukemia: a multicentric international harmonization process. Cytometry Part B-Clinical Cytometry 2006; 70B: 309-314.
10. Matutes E, Attygalle A, Wotherspoon A, et al. Diagnostic issues in chronic lymphocytic leukaemia (CLL). Best Pract Res Clin Haematol 2010; 23: 3-20.
11. B elov L, d e la Vega O, d os Remedios C G, et al. Immunophenotyping of leukemias using a cluster of differentiation antibody microarray. Cancer Res 2001; 61: 4483-4489.
12. Belov L, Mulligan S P, Barber N, et al. Analysis of human leukaemias and lymphomas using extensive immunophenotypes from an antibody microarray. Br J Haematol 2006; 135: 184-197.
13. Huang PY, Best OG, Belov L, et al. Surface profiles for subclassification of chronic lymphocytic leukemia. Leuk Lymphoma 2012; 53: 1046-1056.
14. Wierda WG, Mulligan S, Shelvin B, et al. Surface antigens identified by antibody microarray that correlate with IgV(H) mutational status and ZAP70 expression in CLL. Blood 2005; 106: 826A-826A.
15. H allek M, C heson B D, C atovsky D, et al. Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines. Blood 2008; 111: 5446-5456.
16. Kaufman KL, Belov L, Huang P, et al. An extended antibody microarray for surface profiling metastatic melanoma. J Immunol Methods 2010; 358: 23-34.
17. B elov L, H uang P, B arber N, et al. Identification of repertoires of surface antigens on leukemias using an antibody microarray. Proteomics 2003; 3: 2147-2154.
18. H amelinck D, Z hou H, L i L, et al. Optimized normalization for antibody microarrays and application to serum-protein profiling. Mol Cell Proteomics 2005; 4: 773-784.
19. S ill M, S chroder C, H oheisel J D, et al. Assessment and optimisation of normalisation methods for dual-colour antibody microarrays. BMC Bioinformatics 2010; 11: 556.
20. Eisen MB, Spellman PT, Brown PO, et al. Cluster analysis and display of genome-wide expression patterns. Proc Natl Acad Sci USA 1998; 95: 14863-14868.
21. R ingner M, P eterson C. M icroarray-based cancer diagnosis with artificial neural networks. Biotechniques 2003; (Suppl.) 30-35.
22. Rossi D, Spina V, Bomben R, et al. Association between molecular lesions and specific B-cell receptor subsets in chronic lymphocytic leukemia. Blood 2013; 121: 4902-4905.
23. Buggins AGS, Levi A, Gohil S, et al. Evidence for a macromolecular complex in poor prognosis CLL that contains CD38, CD49d, CD44 and MMP-9. Br J Haematol 2011; 154: 216-222.
24. Gattei V, Bulian P, Del Principe MI, et al. Relevance of CD49d protein expression as overall survival and progressive disease prognosticator in chronic lymphocytic leukemia. Blood 2008; 111: 865-873.
25. N uckel H, S witala M, C ollins C H, et al. High CD49d protein and mRNA expression predicts poor outcome in chronic lymphocytic leukemia. Clin Immunol 2009; 131: 472-480.
26. Quijano S, Lopez A, Rasillo A, et al. Impact of trisomy 12, del(13q), del(17p), and del(11q) on the immunophenotype, DNA ploidy status, and proliferative rate of leukemic B-cells in chronic lymphocytic leukemia. Cytometry B Clin Cytom 2008; 74: 139-149.
27. Z ucchetto A, S onego P, D egan M, et al. Surface-antigen expression profiling of B cell chronic lymphocytic leukemia: from the signature of specific disease subsets to the identification of markers with prognostic relevance. J Transl Med 2006; 4: 11.
28. Hulkkonen J, Vilpo L, Hurme M, et al. Surface antigen expression in chronic lymphocytic leukemia: clustering analysis, interrelationships and effects of chromosomal abnormalities. Leukemia 2002; 16: 178-185.
29. Vilpo J, Tobin G, Hulkkonen J, et al. Surface antigen expression and correlation with variable heavy-chain gene mutation status in chronic lymphocytic leukemia. Eur J Haematol 2003; 70: 53-59.
30. Z ucchetto A, B omben R, D al Bo M, et al. A scoring system based on the expression of six surface molecules allows the identification of three prognostic risk groups in B-cell chronic lymphocytic leukemia. J Cell Physiol 2006; 207: 354-363.
31. Zucchetto A, Sonego P, Degan M, et al. Signature of B-CLL with different prognosis by shrunken centroids of surface antigen expression profiling. J Cell Physiol 2005; 204: 113-123.
32. Drillenburg P, Pals ST. Cell adhesion receptors in lymphoma dissemination. Blood 2000; 95: 1900-1910.
33. Burger JA, Ghia P, Rosenwald A, et al. The microenvironment in mature B-cell malignancies: a target for new treatment strategies. Blood 2009; 114: 3367-3375.
34. Ponzoni M, Doglioni C, Caligaris-Cappio F. Chronic lymphocytic leukemia: the pathologist's view of lymph node microenvironment. Semin Diagn Pathol 2011; 28: 161-166.
35. Stoolman LM. Adhesion molecules controlling lymphocyte migration. Cell 1989; 56: 907-910.
36. C orbi A L, M iller L J, O connor K, et al. cDNA cloning and complete primary structure of the alpha-subunit of a leukocyte adhesion glycoprotein, P150, 95. EMBO J 1987; 6: 4023-4028.
37. Springer TA, Dustin ML, Kishimoto TK, et al. The lymphocyte function-associated LFA-1, CD2, and LFA-3 molecules: cell-adhesion receptors of the immune-system. Annu Rev Immunol 1987; 5: 223-252.
38. Bairey O, Zimra Y, Rabizadeh E, et al. Expression of adhesion molecules on leukemic B cells from chronic lymphocytic leukemia patients with predominantly splenic manifestations. Isr Med Assoc J 2004; 6: 147-151.
39. Plander M, Seegers S, Ugocsai P, et al. Different proliferative and survival capacity of CLL-cells in a newly established in vitro model for pseudofollicles. Leukemia 2009; 23: 2118-2128.
40. G ruber G, S chwarzmeier J D, S hehata M, et al. Basic fibroblast growth factor is expressed by CD19/CD11c-positive cells in hairy cell leukemia. Blood 1999; 94: 1077-1085.
41. Almasri NM, Duque RE, Iturraspe J, et al. Reduced expression of CD20 antigen as a characteristic marker for chronic lymphocyticleukemia. Am J Hematol 1992; 40: 259-263.
42. Grillo-Lopez AJ, Kunkel L. Correspondence re: T. Davis et al, therapy of B-cell lymphoma with anti-CD20 antibodies can result in loss of CD20 antigen expression. Clin. Cancer Res 1999; 5 :611-615
43. Clin Cancer Res 2000; 6: 317-318.
44. Hayat A, McGuckin S, Conneally E, et al. Fludarabine, cyclophosphamide and rituximab: an effective chemoimmunotherapy combination with high remission rates for chronic lymphocytic leukaemia. Irish J Med Sci 2009; 178: 441-446.
45. Ghia P, Guida G, Stella S, et al. The pattern of CD38 expression defines a distinct subset of chronic lymphocytic leukemia (CLL) patients at risk of disease progression. Blood 2003; 101: 1262-1269.
46. Deaglio S, Vaisitti T, Aydin S, et al. In-tandem insight from basic science combined with clinical research: CD38 as both marker and key component of the pathogenetic network underlying chronic lymphocytic leukemia. Blood 2006; 108: 1135-1144.
47. Kung C, Pingel JT, Heikinheimo M, et al. Mutations in the tyrosine phosphatase CD45 gene in a child with severe combined immunodeficiency disease. Nat Med 2000; 6: 343-345.
48. Banchereau J, Bazan F, Blanchard D, et al. The CD40 antigen and its ligand. Annu Rev Immunol 1994; 12: 881-922.
49. de Totero D, Meazza R, Zupo S, et al. Interleukin-21 receptor (IL-21R) is up-regulated by CD40 triggering and mediates proapoptotic signals in chronic lymphocytic leukemia B cells. Blood 2006; 107: 3708-3715.
50. Damle RN, Ghiotto F, Valetto A, et al. B-cell chronic lymphocytic leukemia cells express a surface membrane phenotype of activated, antigen-experienced B lymphocytes. Blood 2002; 99: 4087-4093.
51. E lsner J, H ochstetter R, S piekermann K, et al. Surface and mRNA expression of the CD52 antigen by human eosinophils but not by neutrophils. Blood 1996; 88: 4684-4693.
52. Ginaldi L, De Martinis M, Matutes E, et al. Levels of expression of CD52 in normal and leukemic B and T cells: Correlation with in vivo therapeutic responses to Campath-1H. Leuk Res 1998; 22: 185-191.
53. Albitar M, Do KA, Johnson MM, et al. Free circulating soluble CD52 as a tumor marker in chronic lymphocytic leukemia and its implication in therapy with anti-CD52 antibodies. Cancer 2004; 101: 999-1008.
54. S chweighofer C D, W endtner C M. First-line treatment of chronic lymphocytic leukemia: role of alemtuzumab. Onco Targets Ther 2010; 3: 53-67.
55. Cambiaggi C, Scupoli MT, Cestari T, et al. Constitutive expression of CD69 in interspecies t-cell hybrids and locus assignment to human chromosome-12. Immunogenetics 1992; 36: 117-120.
56. Cho D, Kim YI, Kang JS, et al. Resistance to cytotoxic chemotherapy is induced by NK cells in non-Hodgkin ' s lymphoma cells. J Clin Immunol 2004; 24: 553-560.
57. Del Poeta G, Del Principe MI, Bulian P, et al. Clinical significance of CD69 expression in chronic lymphocytic leukemia. Blood 2010; 116: 1471-1472.
58. Zucchetto A, Cattarossi I, Nanni P, et al. Cluster analysis of immunophenotypic data: the example of chronic lymphocytic leukemia. Immunol Lett 2011; 134: 137-144.
59. Levy S, Todd SC, Maecker HT. CD81 (TAPA-1): a molecule involved in signal transduction and cell adhesion in the immune system. Annu Rev Immunol 1998; 16: 89-109.
60. C lark K L, Z eng Z, L angford A L, et al. PGRL is a major CD81- associated protein on lymphocytes and distinguishes a new family of cell surface proteins. J Immunol 2001; 167: 5115-5121.
61. Diaz LA, Friedman AW, He XG, et al. Monocyte-dependent regulation of T lymphocyte activation through CD98. Int Immunol 1997; 9: 1221-1231.
62. Warren AP, Patel K, McConkey DJ, et al. CD98: a type II transmembrane glycoprotein expressed from the beginning of primitive and definitive hematopoiesis may play a critical role in the development of hematopoietic cells. Blood 1996; 87: 3676-3687.
63. H onda H, I nazawa J, N ishida J, et al. Molecular-cloning, characterization, and chromosomal localization of a novel proteintyrosine- phosphatase, HPTP-ETA. Blood 1994; 84: 4186-4194.
64. de la Fuente-Garcia MA, Nicolas JM, Freed JH, et al. CD148 is a membrane protein tyrosine phosphatase present in all hematopoietic lineages and is involved in signal transduction on lymphocytes. Blood 1998; 91: 2800-2809.
65. A gematsu K, H okibara S, N agumo H, et al. Plasma cell generation from B-lymphocytes via CD27/CD70 interaction. Leuk Lymphoma 1999; 35: 219-223.
66. Porakishvili N, Kulikova N, Jewell AP, et al. Differential expression of CD180 and IgM by B-cell chronic lymphocytic leukaemia cells using mutated and unmutated immunoglobulin VH genes. Br J Haematol 2005; 131: 313-319.
67. P orakishvili N, M emon A, V ispute K, et al. CD180 functions in activation, survival and cycling of B chronic lymphocytic leukaemia cells. Br J Haematol 2011; 153: 486-498.
68. Baba M, Imai T, Nishimura M, et al. Identification of CCR6, the specific receptor for a novel lymphocyte-directed CC chemokine LARC. J Bio Chem 1997; 272: 14893-14898.
69. Matesanz-Isabel J, Sintes J, Llinas L, et al. New B-cell CD molecules. Immunol Lett 2011; 134: 104-112.
70. Gavrieli M, Sedy J, Nelson CA, et al. BTLA and HVEM cross talk regulates inhibition and costimulation. Adv Immunol 2006; 92: 157-185.